DAHUA-TECHNOLOGY
7.9.2021 15:47:05 CEST | Business Wire | Press release
Dahua Technology, a world leading video-centric smart IoT solution and service provider, has launched its upgraded Three-in-One Camera series – the TiOC 2.0 . It is equipped with intelligent features that can help ease your monitoring operation and customize your alarm system based on your actual needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005426/en/
Smart Dual Illuminators
The TiOC 2.0 features Smart Illumination Mode (default mode) that turns on the white light when a target is detected (PTZ camera tracks the target). The active alarm (siren and red & blue light) will be triggered if the target enters the rule area. When the target leaves the monitored area, the white light turns off (PTZ camera goes back to preset) and the IR illuminator turns back on, which helps reduce light pollution at night.
VoiceCatcher Technology
The Dahua VoiceCatcher technology adopts a high-sensitivity dual mic array – a newly designed audio acquisition circuit that can intercept external circuit interference. With Dahua’s self-developed noise reduction algorithm and high-performance SOC, it increases the camera’s audio pick-up distance by 7 meters (based on standard laboratory environment). Combined with built-in speaker, VoiceCatcher greatly enhances the device’s Two-way Talk function.
Better Image
The OPC (Optical Path Compensation) technology enables TiOC 2.0 cameras to correct the angle of refraction of different light rays, allowing Dahua IPCs to output brighter and clearer black & white images with F1.0 large aperture lens. It increases the light input by 1.96 times and 2.56 times compared with F1.4 and F1.6 respectively. Also, the upgraded hardware and software provide a smooth visual experience (4K @25/30 fps) even with enabled AI.
Other Features
TiOC 2.0 supports configuration of alarm-in ports directly on the webpage interface. Aside from Perimeter Protection , SMD 3.0 and Active Deterrence , this series is also equipped with Auto Tracking 3.0 (via PTZ camera) that utilizes a deep fusion of intelligent and focusing algorithms (PFA 3.0), providing longer tracking distance of up to 870 meters.
Conclusion
Overall, the upgraded Dahua TiOC 2.0 offers innovative features that allow users to customize their monitoring systems. With new features such as Smart Dual Illuminators, VoiceCatcher technology, OPC, and Auto Tracking 3.0, this series embodies Dahua Technology’s dedication to “Innovation, Quality and Service” in order to serve its partners and customers around the world.
Note:
Full-color 2.0 & TiOC 2.0 Online Launch Conference
September 14, 2021 (17:00-18:00 Beijing Time)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005426/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom